Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Cellular immunotherapies represent a promising approach for the treatment of cancer. Engineered adoptive cell therapies redirect and augment a leukocyte’s inherent ability to mount an immune response by introducing novel anti-tumor capabilities and targeting moieties. A prominent example of this app...
Guardado en:
Autores principales: | Christopher Sloas, Saar Gill, Michael Klichinsky |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/00815eb322fe41ae977bcde18dd243c7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
por: Mehran Bahraini, et al.
Publicado: (2021) -
Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies
por: Jessica Waibl Polania, et al.
Publicado: (2021) -
CELLULAR IMMUNOTHERAPY: A MODERN APPROACH TO TREATMENT OF ONCOLOGICAL DISEASES
por: Yu. N. Lezhnin, et al.
Publicado: (2018) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Cristina Aparicio, et al.
Publicado: (2021) -
How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover M, et al.
Publicado: (2021)